Progyny, Inc.
Progyny provides fertility, family building and women’s health benefits to employers for their employees and covered dependents. Its offerings include fertility benefits built around Smart Cycle treatment bundles, concierge support from Progyny Care Advocates, access to a network of fertility specialists and the integrated Progyny Rx pharmacy benefits solution. Other services address pregnancy and postpartum, menopause and midlife, benefit and leave navigation, parent and child wellbeing, and reimbursement for certain adoption, surrogacy, doula and travel expenses. Progyny Global provides country-specific support for fertility, family building and women’s health benefits. Progyny contracts with employers to provide and administer these benefit programs, including managing access to providers, member support, pharmacy services and eligible reimbursements. It serves over 590 employers in the United States and has contracts covering approximately 7.2 million employees and dependents. The company is headquartered in New York, New York.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Leerink Partners kept its Outperform rating on Progyny and increased its price target to $38 from $37, suggesting a 26.2% upside from the Nov 4 close of $30.10. Recent analyst price targets for Progyny range from $35 to $38.
Wells Fargo raised its price target for Progyny to $38 from $37, maintaining an Overweight rating. This implies a 26.2% upside from the Nov 4 close of $30.10.
Cantor Fitzgerald kept Progyny at Overweight, raising its price target to $35 from $31, a 12.9% increase. This implies a 16.3% upside from the Nov 4 close of $30.10.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning PGNY (Progyny, Inc.). Coverage has skewed bullish: 13 bullish, 1 neutral, and 0 bearish.
Recent PGNY coverage spans financial news, earnings and market movers.
In the last 30 days, PGNY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($117K). The most active reporter was Cummings Melissa B, Chief Operating Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade suggests potential upside.
Analyst upgrade suggests upside potential for the stock.
Analyst upgrade suggests upside potential for Progyny.
Target raise and higher guidance suggest upside potential for PGNY.
The earnings beat on a per‑share basis and the guidance range suggest modest upside if expectations were lower.
AlphAI scores every news story that mentions PGNY with an AI model for sentiment and relevance, and aggregates insider trades from Progyny, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Leerink Partners kept its Outperform rating on Progyny and increased its price target to $38 from $37, suggesting a 26.2% upside from the Nov 4 close of $30.10. Recent analyst price targets for Progyny range from $35 to $38.
Wells Fargo raised its price target for Progyny to $38 from $37, maintaining an Overweight rating. This implies a 26.2% upside from the Nov 4 close of $30.10.
Cantor Fitzgerald kept Progyny at Overweight, raising its price target to $35 from $31, a 12.9% increase. This implies a 16.3% upside from the Nov 4 close of $30.10.
Citizens raised its price target for Progyny (PGNY) to $38.00 from $33.00, citing increased guidance. The firm adjusted its 2027 revenue estimate to $1.526B and raised its Q4 revenue estimate to $360M. Progyny's Q3 2026 earnings beat expectations, with revenue of $341.25M and EPS of $0.32. The company added 1.3M new covered lives and 85 new clients.
Progyny Inc. (PGNY) reported Q3 earnings of $26.3M, or 32 cents per share, with adjusted EPS of 52 cents. Revenue was $341.3M. The company forecasts Q4 EPS of 53-58 cents and revenue of $344.7M-$364.7M. Full-year EPS is expected to be $2.09-$2.13 on revenue of $1.37B-$1.39B.
Progyny, Inc. (PGNY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Progyny, Inc. Announces Third Quarter 2026 Results Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income Selling Season Yields Record 1.3 Million New Covered Lives with Another Year of Near 100% Retention Raises Midpoint of Full Year Guida
Progyny (PGNY) lowered its full-year revenue guidance to $1.36–$1.385B from $1.365–$1.405B due to softer-than-expected utilization trends. The company attributes this to seasonal factors, not structural demand shifts. Snow Capital Small Cap Value Fund noted PGNY as a Q3 performance detractor, despite long-term optimism. PGNY closed at $28.40 with a $2.18B market cap, up 12.56% monthly and 51.79% yearly.
Progyny (PGNY) shares rose 6% after announcing a record 1.2 million new covered lives expected by mid-2027. The company's Q1 2026 revenue guidance of $325.5M missed estimates by 5.1%. Despite a 7.3% YTD gain, shares trade 14.7% below their 52-week high.
Progyny (PGNY) expects to add 1.2 million new covered lives by 2027, driven by employer demand for cost-effective fertility solutions. CEO Pete Anevski attributes growth to employers seeking benefit managers with proven cost management amid rising medical costs. The company offers accelerated contracting for 2027 expansions.
Wells Fargo initiated coverage on Progyny (PGNY) with an Overweight rating and a $37.00 price target. The stock is trading at $24.89, with a GF Value™ of $29.11, indicating a 14.5% undervaluation. PGNY has a GF Score™ of 96/100, reflecting strong financial performance. The company specializes in fertility and women's health benefits management, with a market cap of $1.91 billion.
